Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Efficacy of Cryoablation in Patients with Obesity
Author(s): Aiko Takami , Junichiro Miake , Masaru Kato , et al Added: 1 year ago

Demographic

Electrophysiology & Arrhythmia
ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 7 months ago
ESC 2023 – Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss the findings from the STEP HFpEF trial (NCT04788511). Around half of patients with heart failure have heart failure with preserved ejection fraction (HFpEF), and most patients with HFpEF are overweight or obese. Patients with… View more

Heart Failure

Prevention & Chronic Conditions
AHA 23 Late-Breaker Discussion: The SELECT Trial
Author(s): A Michael Lincoff , Harriette Van Spall Added: 5 months ago
AHA 2023 — Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) sat down with Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the SELECT trial (NCT03574597).In this randomized, double-blind, parallel-group, placebo-controlled trial sponsored by Novo Nordisk, semaglutide was compared with a placebo in patients who have overweight or obesity and a history of… View more

Standards & Guidelines

Prevention & Chronic Conditions
AHA 23: 3 Trials That Will Change My Practice
Author(s): Dipti Itchhaporia Added: 4 months ago
AHA 23 - Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, US), interventional cardiologist and Past President of the American College of Cardiology (ACC) highlights the top three late-breaking science trials from the 2023 AHA Scientific Sessions with the potential to change medical practices.Trials discussed in detail include:SELECT: Semaglutide and Cardiovascular Outcomes in Obesity… View more

Anticoagulation

Standards & Guidelines
View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 4 months ago
What's hot at #AHA23?Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the late-breaking science data from AHA Scientific Sessions 2023.They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.Trials Covered00:20 - DAPA… View more

Anticoagulation

Standards & Guidelines
CardioNerds @AHA23: SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients
Author(s): A Michael Lincoff , Ahmed Ghoneem Added: 4 months ago
AHA 2023 - Investigator, Dr A Michael Lincoff (Cleveland Clinic, US) is interviewed by Dr Ahmed Ghoneem (UPMC Harrisburg, US), CardioNerds Ambassador, on the findings of the SELECT Trial (NCT03574597).SELECT is a randomised trial aiming to determine if semaglutide can reduce the risk of cardiovascular events in patients with overweight or obesity and prior cardiovascular disease. 17609 patients… View more

Standards & Guidelines

Prevention & Chronic Conditions
Underweight Among Filipinos
Author(s): Bryan Rene F Toledano , Gerald C Vilela Added: 1 year ago

Vascular Disease and Surgery
Allometric Indexing of LVM
Author(s): Anders Sahlén , Muh Tyng Teo , Nadira Hamid , et al Added: 1 year ago

Imaging & Diagnostics

Prevention & Chronic Conditions
AHA 23: Preventive Cardiology in 2023
Author(s): Michael Honigberg Added: 4 months ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation… View more

Standards & Guidelines

Prevention & Chronic Conditions
AHA 2023 Late-Breaking Science Lineup Revealed
Added: 6 months ago Source:  AHA, Jordan Rance
The American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals. Among the event’s highlights are eight late-breaking trial sessions, as listed below. Watch our coverage of… View more